On October 28, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced a registered direct offering of 1,146,000 shares of its common stock at a price of $2.83 per share. The offering, which is expected to close on October 29, 2024, is anticipated to generate gross proceeds of approximately $3.2 million before deducting fees and expenses. BioVie has entered into an agreement with ThinkEquity LLC, who will act as the placement agent. In addition to the share offering, BioVie issued a warrant to ThinkEquity, allowing the purchase of additional shares at a future date. The company plans to use the net proceeds for working capital and general corporate purposes. The shares and warrants were offered under a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. The offering is subject to customary closing conditions, and the company has made forward-looking statements regarding the expected completion of the offering.

On October 28, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced a registered direct offering of 1,146,000 shares of its common stock at a price of $2.83 per share. The offering, which is expected to close on October 29, 2024, is anticipated to generate gross proceeds of approximately $3.2 million before deducting fees and expenses. BioVie has entered into an agreement with ThinkEquity LLC, who will act as the placement agent. In addition to the share offering, BioVie issued a warrant to ThinkEquity, allowing the purchase of additional shares at a future date. The company plans to use the net proceeds for working capital and general corporate purposes. The shares and warrants were offered under a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. The offering is subject to customary closing conditions, and the company has made forward-looking statements regarding the expected completion of the offering.